Biotech VC Webinar Launches with Top Experts, Thousands Registered
We'll be gearing up today's webinar on biotech venture capital at the top of the hour. Great guests, great topics. If this is a central issue in your life, tune in. Thousands have signed up already. https://t.co/c16y04mFsD
Makary Slams FDA, Defends Rare Disease Drugs Amid Controversy
You've got to watch this Makary interview on CNBC. He attacks a drug, hits the Old FDA and circles all the wagons around Vinay Prasad, who "loves President Trump" and faces a fatwa (WSJ). Makary is getting major props for...
DIY Gut Microbiome Tests Are Unreliable and Flawed
Direct-to-consumer gut microbiome assessments are unreliable, problematic: a review of 7 companies with significant methodologic issues https://t.co/atwmZUNjVE https://t.co/SqlMljuW0y
FDA Chief Backs Rare Disease Rejections, Lauds Vinay Prasad
FDA Commissioner Marty Makary defends rare disease drug rejections, Vinay Prasad "Vinay Prasad is a genius,” Makary said. “He’s on loan from UCSF. He’s published over 500 scientific peer-reviewed articles, and some of the drugs they are criticizing him for...
Ten Near‑Term AI Predictions Shaping Healthcare
I've written so much about various details of healthcare's AI revolution that it was time to come up with a high-level overview of what we can certainly expect from AI in the next few years. 10 predictions, coming from four...
Orforglipron Outperforms Other Oral GLP‑1s in T2D Trial
Head-to-head trial of the oral GLP-1 drugs in people with T2D. Orforglipron was superior https://t.co/9B7RXIgdJY
FDA Chief Warns Against Approving Risky, Ineffective Rare‑disease Drugs
$QURE down this morning on comments made by FDA Commissioner Marty Makary to CNBC's Becky Quick. In a discussion about rare-disease drug approvals and Vinay Prasad, Makary said this: "I think there has been a bit of an effort to...
Progress Toward Off‑the‑Shelf Vaccines for Hereditary Cancer
We're making headway for off the shelf preventive cancer vaccines in people with hereditary forms of cancer, e.g. Lynch syndrome https://t.co/F3LqKS46BQ
AI Integrates Health Data for Early Outbreak Detection
AI is entering public health infrastructures, connecting epidemiology, clinical data, and research into shared intelligence. When models flag outbreaks early and automate routine tasks, health systems allocate resources with precision and reduce delays. Microblog @antgrasso https://t.co/nuhbxsiFX3
OrbiMed Leads Top Five Biotech VC Dealmakers
Always fun to look over @JohnCendpts annual list of the top 100 most active VCs in biotech for the past year Top 5, by # of rounds: 1. OrbiMed 2. RA Capital 3. GV 4. General Catalyst 5. Catalio Full list & analysis is live...
RVMD Switches PRMT5 Partner From T
$RVMD was collaborating with $TNGX in PRMT5, but now it's working with $BMY (remember that ex MRTX project?). Via @ByMadeleineA @ApexOnco -> https://t.co/mGZjKOiB7p (And $AMGN still dose optimising.)
AI in Healthcare: Ethics, Trust, and Clinician Adaptation
A meaningful share: AuthorsReading posted an editorial review of The Doctor’s Future. They spotlight the book’s focus on the real-world questions behind AI/robotics in healthcare—privacy, accountability, ethics, patient trust, and how clinicians can adapt their roles with clarity (supported by the...
Smart Pills: Diagnostics Now, Autonomous Therapy Still Years Away
IEEE has a very technical overview of ingestible electronics and tomorrow's smart pills that could one day deliver drugs and take biopsies. To "take actions based on its findings" is a bit too far-fetched for now. What can these technologies definitely...
Measuring ROI for Clinician-Facing AI Tools
I enjoyed working with an all-star team – the great @LisaRotenstein @UCSF and @DBatesSafety of @BrighamWomens – on this paper describing how to measure return on investment (ROI) for clinician-facing AI tools. @JAMAInternalMed https://t.co/uvhb1qI7mG
GLP‑1 Drugs Plus Healthy Habits Cut Heart Events
The combination of GLP-1 drugs (such as Ozempic) and healthy lifestyle factors was associated with less major adverse cardiovascular events in ~100,000 people with T2D @TheLancetEndo https://t.co/phNzEBy7zY https://t.co/DDVi8uedRP
Linking Glucose Control to Vascular Health: Diabetes' Next Frontier
From glucose to vascular health: the future of diabetes care https://t.co/UMhK4BkOE3 #Conditions #Diabetes via @kevinmd
Clinical AI's Future Hinges on Knowledge Integrity Over Architecture
AI isn’t just exposing workflow gaps in healthcare — it’s exposing content fragmentation. The future of clinical AI may depend less on model architecture and more on knowledge integrity. More from @ElsevierConnect at #ViVE2026.👇👇 https://t.co/zbay0c1z1x
Psychedelic Stocks Overhyped as Nominee Warns Caution
Psychedelic tape still trades on vibes > policy. Surgeon General nominee Casey Means says she “would not recommend” psilocybin to the American people today. Yes, she nods to “exciting work” in PTSD and veterans. But that is a far cry from...
AI Expands Beyond Scribes to Entire Healthcare Practice
The future isn’t just AI scribes — it’s AI across the whole practice. Front desk to billing. Hear Venky Chellappa share @charmhealth's approach at #ViVE2026 👇 https://t.co/Fu8iReWUAZ
Regulatory Pressure Forces Hospitals Back to Fax
When government requirements increase data sharing but systems aren’t connected, the fax machine fills the gap. Jess Czelusniak shares what that reality looked like at VHC Health.👇 Hear more about their experience: https://t.co/D7oXKCb2Kg @VyneMedical @VHCHealth #eFax #HITSM https://t.co/mvrhQyx04R
Oracle Health Sets New Standard for Healthcare Interoperability
The @OracleHealth team isn't waiting for the future of healthcare connectivity—we’re setting the standard: https://t.co/Gw7WFnvODg Through this validation program, we’re building trusted relationships with device vendors, streamlining interoperability, and opening the door for continued collaboration and innovation.
FDA Rejects Experimental Rare Blood Cancer Therapy
An experimental therapy for a rare blood cancer was on the path toward approval by the Food and Drug Administration last year — with internal reviewers recommending it be cleared — before the agency rejected the drug last month, @adamfeuerstein...
FDA Rejects Europe‑approved Drug: What Shifted?
Interesting read: the thread and the story. A drug that was approved in Europe in 2022, which looked like it was on track for #FDA approval, instead is rejected. What changed at FDA? 🤔
ACIP Meeting Notice Raises Questions on Vaccine Injury Role
The Federal Register notice for the (now) March #ACIP meeting is now up & it's ... puzzling. Possible vote on Covid vaccine injury? ACIP can recommend changes to the way a vaccine is used, for safety reasons. But vaccine injuries aren't...
Dual BCMA‑CD19 Targeting Shows Promise in ASyS
interesting and different efficacy outcomes in ASyS and SSc autoimmune patients treated with blinatumomab (CD3/CD19) and teclistamab (CD3/BCMA), respectively, + Rituximab maintenance. Potential for targeting both BCMA and CD19, especially in ASys. https://t.co/Dyq7h9EeGo
No Pharma Money, Proven Vaccines Safe for Autistic Kids
Haha what an original and inspired conspiracy trope. Search my name in CMS Open Payments. I get $0 from pharma companies. ZERO. ZILCH. I do this because I believe in public health and keeping kids from getting serious illnesses. And because, unlike...
Stem Cell Therapy Boosts Frailty Walk Test Performance
A randomized trial of a stem cell therapy vs placebo for aging frailty showed durable and dose-dependent improvement in the 6-minute walk test @CellStemCell https://t.co/2jOYuIgUrY https://t.co/04mEV7OdLo
Online Communities Bridge
Online Patient Communities for the E-Patient “Betwixt & Between” a New Pt & an Expert [Aug 29, 2013] @mtmdphd #ASCOConnection https://t.co/IxinXTK715 #mmsm
Identifying Key Barriers to Boost Myeloma Trial Enrollment
Identification of Significant Barriers to Accrual (BtA) to @theNCI Sponsored Multiple Myeloma – Clinical Trials (MM-CT): A Step towards Improving Accrual to #ClinicalTrials - @mweissmdphd et al. #ASH12 Abstract 3165 https://t.co/i4zO7ktqHJ #mmsm #caxtx #ctsm
Quadruplet Therapy Effective without Early Transplant in NDMM
#EAOnc EQUATE EAA181 Effective Quadruplet Utilization After Tx Evaluation: Ph3 RCT NDMM Not Intended for Early ASCT [Activated: 10/27/20] PI= @myelomaMD https://t.co/qD26HMx3J8 #NCT04566328 #mmMRD #mmsm @eaonc @mweissmdphd @VincentRK @LynneWagnerPhD Wei Snyder Kostakoglu @mtmdphd
Phase 3 Trial Tests Daratumumab Regimens for New AL Amylo
.@SWOG S2213 Ph3 RCT Dara-VC Induction Followed by ASCT or Dara-VCD Consolidation & Daratumumab Maintenance in Pts w/ Newly Diagnosed AL Amyloidosis [Activated: 12/1/23] https://t.co/OizUfJCc2c #mmsm #bmtsm https://t.co/uikUnnJd3n
Super Agers Generate More Neurons Than Much Younger Adults
New @Nature The brains of Super Agers produce more neurons than people some 40 years younger, a neurogenesis resilient signature linked to exceptional cognitive health and memory skills https://t.co/tNB0dTea2F
New Guidelines Define Prior Therapy Lines in Multiple Myeloma
Guidelines for determination of the number of prior lines of therapy in multiple myeloma [Aug 13, 2015] @VincentRK , Richardson, San Miguel @BloodJournal https://t.co/Tdmr2gTUi6 #mmsm #ctsm #ClinicalTrials https://t.co/ZOobout75Q
PI‑Rd Triplets Show Superior Efficacy And
Comparative Effectiveness and Safety of PI-Rd Triplets in Relapsed/Refractory Multiple Myeloma: INSIGHT-MM Data Analysis [Jan 13, 2026] @NoemiPuigM et al. European Journal of Haematology https://t.co/Vf7USecLlR #NCT02761187 #mmsm #openaccess https://t.co/C5Ya6TTQfo
Combining EMR and Multi‑omics Sharpens Biological Age Predictions
Assessment of biological age integrating electronic medical records and multi-omics increases accuracy for predicting outcomes @NatureAging https://t.co/7y60SSPTQf https://t.co/u02OlWMdQz
GSK's New CEO Targets Proven Science, Eyes Obesity Drugs
The FT's report on GSK's $950M deal to buy 35Pharma and its pulmonary arterial hypertension drug includes an interesting unnamed insider's quote that new CEO Luke Miels is going after assets where "the science is relatively settled." Maybe leaning into...
Circulating piRNAs May Predict Elderly Survival and Longevity
Strong claim that needs independent replication: "Our findings provide compelling evidence that circulating smRNAs—especially piRNAs—are powerful predictors of survival in older adults and potential biomarkers of longevity" https://t.co/oi4220zxGY https://t.co/yk3MX4VdQj
Fasting Insulin: The Overlooked Test Predicting Disease
The Most Important Blood Test Your Doctor Doesn't Order You can have normal blood sugar, normal A1C, and normal cholesterol… and still be metabolically sick. In this episode, Dr. Robert Lufkin explains why fasting insulin may be the single most important blood...
Novo's Vivtex Deal Could Unlock Superior Oral Obesity Meds
With Vivtex deal, Novo gains a chance at better oral obesity drugs https://t.co/DhIelbC9jI by @gwendolynawu $NVO #obesity
Dr. Hotez Warns of America's Vaccination Crisis
Stand Up! with Pete Dominick: 1538 Dr Peter Hotez on the state of Vaccination in America. My latest with @PeteDominick https://t.co/LsuvmglNBx
2026’s Top 100 Digital Health & AI Innovators Unveiled
I’m proud to introduce 𝐓𝐡𝐞 𝐌𝐞𝐝𝐢𝐜𝐚𝐥 𝐅𝐮𝐭𝐮𝐫𝐢𝐬𝐭’𝐬 𝟏𝟎𝟎 𝐃𝐢𝐠𝐢𝐭𝐚𝐥 𝐇𝐞𝐚𝐥𝐭𝐡 𝐚𝐧𝐝 𝐀𝐈 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐨𝐟 𝟐𝟎𝟐𝟔! The digital health and AI fields are saturated with hype, and distinguishing the promising players from the noise is a challenge. The annual list is our...
TrumpRx Cuts Cash Prices, but Offers Little New Savings
President Trump negotiated lower prices for some drugs on TrumpRx, but discounts only apply to cash paying patients not using their insurance. Many drugs already had big discounts through manufacturers or coupons, and some have generic equivalents that are already...
Trump Pushes Secret Drug Deals Into Law Despite Opacity
President Trump has called for his deals with drug companies to be enacted into legislation. It's hard to know what that means since the deals are not public.
FDA Says Data, Not Numbers, Prove IBRX Benefit
Th FDA is absolutely correct, and confirms what I’ve said all along. This $IBRX @DrPatrick “lymphopenia” push means nothing until or unless they come up with real data showing patient benefit. The “number” doesn’t matter.
Biotech Embraces Data‑Driven Mornings, Gains Afternoons
I love that biotech has returned to the "data in the morning, raise in the afternoon" way of living its best life. $VIR $PVLA
Edge Computing Brings Millisecond Decisions to Critical Industries
When decisions depend on milliseconds, moving data closer to where work happens matters. Edge computing and edge AI are reshaping manufacturing, energy, healthcare, and smart infrastructure, where latency, autonomy, and reliability are critical. More: https://t.co/0MYapoejKN @TMobileBusiness Partner
1
Given 1mg/week of Zepound showed 0.7% reduction in A1c in trials, and so is actually an efficacious dose, this microdose would just be $30/month. (Would imply using for longer than recommended after opening).
Hepta‑refractory Myeloma Arises via Sequential CD38
The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D [Feb 17, 2026] Riedhammer et al. @LeukemiaJnl https://t.co/EyGBz7sEQz #mmsm #PrecisionMedicine #caxtx
Real‑time CME Integrates Evidence Guidelines Into Patient Care
Continuing medical education doesn’t have to mean stepping away from patients. Colin Banas, MD, explains how real-time access to evidence-based guidelines can reinforce learning and support patient care. 🔗https://t.co/BOGg49TELs @DrFirst @ElsevierConnect #CMEs #HITSM https://t.co/cGEozKOfKU
Vir Surges After Astellas Partnership and T‑cell Data
Vir climbs on Astellas deal, study results for ‘masked’ T cell engager https://t.co/336c9FJdjt by @Lilah_Alvarado $VIR + 27% $JANX $ALPMY